核医学/放射性医薬品の世界市場...市場調査レポートについてご紹介

1 Introduction (Page No. – 19)
1.1 Objectives of Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 23)
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Key Industry Insights
2.3 Key Data From Primary Sources
2.4 Key Insights From Primary Sources
2.5 Market Size Estimation Methodology
2.5.1 Research Design
2.6 Market Data Validation and Triangulation
2.7 Assumptions for the Study

3 Executive Summary (Page No. – 33)
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights (Page No. – 39)
4.1 Global Nuclear Medicine Market
4.2 SPECT Nuclear Medicine/Radiopharmaceuticals Diagnostics Market, By Region and Application
4.3 Regional Snapshot of the Nuclear Medicine/Radiopharmaceuticals Market
4.4 Nuclear Medicine/Radiopharmaceuticals Market, By Type (2015 vs. 2020)

5 Market Overview (Page No. – 43)
5.1 Introduction
5.2 Market Segmentation
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Increasing Preference for SPECT and PET Scans
5.3.1.2 Advances in Radiotracers
5.3.1.3 Alpha Radio Immunotherapy-Based Targeted Cancer Treatment
5.3.1.4 Increasing Incidence of Cancer and Cardiac Ailments
5.3.2 Restraints
5.3.2.1 Shorter Half-Life of Radiopharmaceuticals Restricts Its Usage
5.3.2.2 Stringent Regulatory and Gmp Guidelines
5.3.2.3 Competition From Conventional Diagnostic Procedures
5.3.3 Opportunities
5.3.3.1 Potential Radioisotopes in the Pipeline
5.3.3.2 High Demand in Emerging Markets
5.3.3.3 Neurological Applications
5.3.4 Threat
5.3.4.1 Shutdown of Nuclear Reactors

6 Global Nuclear Medicine/Radiopharmaceuticals Market, By Type (Page No. – 56)
6.1 Introduction
6.2 Nuclear Medicine/Radiopharmaceuticals Diagnostic Market
6.2.1 SPECT
6.2.1.1 Technetium-99m (TC-99m)
6.2.1.2 Thallium-201 (TL-201)
6.2.1.3 GAllium-67 (GA-67)
6.2.1.4 Iodine (I-123)
6.2.1.5 Others
6.2.2 PET Radiopharmaceuticals
6.2.2.1 Fluorine-18 (F-18)
6.2.2.2 Rubidium-82 (RB-82)
6.2.2.3 Others
6.3 Nuclear Medicine Therapeutic Isotopes Market
6.3.1 Beta Emitters
6.3.1.1 Iodine-131 (I-131)
6.3.1.2 Yttrium-90 (Y-90)
6.3.1.3 Samarium-153 (SM-153)
6.3.1.4 Rhenium-186 (Re-186)
6.3.1.5 Lutetium-177 (Lu-177)
6.3.1.6 Others
6.3.2 Alpha Emitters
6.3.2.1 Radium-223 (RA-223)
6.3.3 Brachytherapy
6.3.3.1 Cesium-131
6.3.3.2 Iodine-125
6.3.3.3 Palladium-103
6.3.3.4 Iridium-192
6.3.3.5 Others

7 Global Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume (Page No. – 88)
7.1 Introduction
7.2 Diagnostics Market
7.2.1 SPECT Radiopharmaceuticals
7.2.2 PET Radiopharmaceuticals
7.3 Therapeutic Market
7.3.1 Beta Emitters
7.3.2 Alpha Emitters
7.3.3 Brachytherapy

8 Global Nuclear Medicine/Radiopharmaceuticals Market, By Application (Page No. – 101)
8.1 Introduction
8.2 Diagnostics
8.2.1 SPECT
8.2.1.1 Cardiology
8.2.1.2 Lymphoma
8.2.1.3 Neurology
8.2.1.4 Thyroid
8.2.1.5 Other Diagnostic Applications
8.2.2 PET
8.2.2.1 Oncology
8.2.2.2 Cardiology
8.2.2.3 Neurology
8.2.2.4 Other PET Applications
8.3 Therapeutics
8.3.1 Thyroid
8.3.2 Bone Metastasis
8.3.3 Lymphoma
8.3.4 Endocrine Tumors
8.3.5 Other Therapeutic Applications

9 Global Nuclear Medicine/Radiopharmaceuticals Market, By Region (Page No. – 129)
9.1 Introduction
9.2 Diagnostic Market
9.2.1 North America
9.2.1.1 Development of Mo-99 Production Facilities in the U.S.
9.2.1.2 Fda Approvals of New Radiopharmaceuticals
9.2.1.3 Extension of Operations in the Canadian National Research Universal (NRU) Reactor
9.2.1.4 Development of Alternative Medical Isotope Technologies in Canada
9.2.2 Europe
9.2.2.1 Increasing Acceptability of 18f-Fdg PET-CT in the U.K.
9.2.2.2 Shutdown of French Nuclear Reactor
9.2.2.3 New Irradiation Facility in Germany
9.2.3 Asia-Pacific
9.2.3.1 Introduction of New Cost-Effective TC-99 Generators in India
9.2.3.2 High Incidence of Cancer and Cardiovascular Disease in China
9.2.3.3 Increasing Mo-99 Production in Australia
9.2.3.4 Initiatives to Promote Health in Asia-Pacific
9.2.4 Rest of the World
9.2.4.1 Development of Multipurpose Research Reactor in Brazil
9.2.4.2 Argentina’s Increasing Irradiation Capacity
9.2.4.3 Conversion of the Safari 1 Reactor, From Heu-Based Mo-99 Production to Leu
9.3 Therapeutic Market
9.3.1 North America
9.3.1.1 Fda Approval for Alpha Emitters in the U.S.
9.3.1.2 Therapeutic Nuclear Medicine, an Alternative Choice of Treatment in Oncology
9.3.1.3 Increase in the Incidence of Thyroid Cancer
9.3.1.4 Expertise in Isotope Production
9.7.5 Government Initiatives
9.7.6 High Incidence of Cancer
9.3.2 Europe
9.3.2.1 Increasing Awareness of Radioisotope Therapy in the U.K.
9.3.2.2 Adverse Reactions to Radiopharmaceuticals in France
9.3.2.3 Radionuklidtherapeutika—Research Program Conducted in Germany
9.3.2.4 Russia, an Upcoming Country for Radionuclide Therapy
9.3.3 Asia-Pacific
9.3.3.1 Increased Production of Radiopharmaceuticals for Therapeutic Purposes in India
9.3.3.2 Aging Population and Increasing Cancer Incidence
9.3.3.3 Approval of Radium (223 RA) Dichloride By the Therapeutic Goods Administration (TGA)
9.3.4 Rest of the World(RoW)
9.3.4.1 Growing Aging Population
9.3.4.2 Increase in Cancer Incidences

10 Competitive Landscape (Page No. – 177)
10.1 Overview
10.2 Market Share Analysis
10.2.1 Introduction
10.2.2 Cardinal Health, Inc.
10.2.3 Mallinckrodt PLC
10.2.4 GE Healthcare
10.2.5 Lantheus Medical Imaging, Inc.
10.2.6 Bayer Healthcare
10.3 Competitive Situation and Trends
10.3.1 Introduction
10.3.2 Agreements, Contracts, and Partnerships
10.3.3 Acquisitions
10.3.4 Market Development
10.3.5 Expansion
10.3.6 New Product Launches
10.3.7 Others

11 Company Profiles (Page No. – 193)
11.1 Introduction
11.2 Cardinal Health, Inc.
11.2.1 Business Overview
11.2.2 Products and Services
11.2.3 Recent Developments
11.2.4 MnM View
11.3 Mallinckrodt PLC
11.3.1 Business Overview
11.3.2 Product Offerings
11.3.3 Recent Developments
11.3.4 MnM View
11.4 GE Healthcare
11.4.1 Business Overview
11.4.2 Product Portfolio
11.4.3 Recent Developments
11.4.4 MnM View
11.5 Lantheus Medical Imaging, Inc.
11.5.1 Business Overview
11.5.2 Product Offerings
11.5.3 Recent Developments
11.5.4 MnM View
11.6 Bayer Healthcare
11.6.1 Business Overview
11.6.2 Product Offerings
11.6.3 Recent Developments
11.6.4 MnM View
11.7 Bracco Imaging S.P.A
11.7.1 Business Overview
11.7.2 Product Offerings
11.7.3 Recent Developments
11.8 Eczcibasi-Monrol Nuclear Products
11.8.1 Business Overview
11.8.2 Products and Services
11.8.3 Recent Developments
11.9 Nordion, Inc.
11.9.1 Business Overview
11.9.2 Product Offerings
11.9.3 Recent Developments
11.10 Advanced Accelerator Applications S.A.
11.10.1 Business Overview
11.10.2 Product Offerings
11.10.3 Recent Developments
11.11 IBA Molecular Imaging
11.11.1 Business Overview
11.11.2 Product Offerings
11.11.3 Recent Developments

12 Appendix (Page No. – 218)
12.1 Discussion Guide
12.2 Company Developments (2012–2015)
12.2.1 Cardinal Health, Inc.
12.2.2 Bayer Healthcare
12.3 Available Customizations
12.4 Introducing RT: Real-Time Market Intelligence
12.5 Related Reports